We Regulate Wrinkles Like We Regulate Cancer

The oncology bar, applied to beauty

Here is the fact that explains most of the friction. Regulatory agencies evaluate aesthetic products using essentially the same logic they apply to oncology, to diabetes, to immunology, to the most serious therapeutic categories in medicine. To earn an approval, a product must demonstrate a quantitative improvement on a validated scale, in a well-powered pivotal trial, sustained over a defined period, with the statistical rigor of two adequate and well-controlled studies in the case of a drug. It must clear that bar against a standard designed for interventions where lives are at stake. This is a statistical endpoint, a demonstration that a measurable difference on a photonumeric scale is unlikely to have arisen by chance. It is a perfectly sensible thing to demand of a cancer therapy. It was never designed to describe what would be clinically meaningful in aesthetic practice. The thing that makes a patient happy in a treatment room is the natural movement, the harmony, the subtle and combination-dependent and technique-driven result. That bears almost no resemblance to the isolated, maximally standardized, single-variable improvement a validated scale is built to detect. The endpoint that earns the approval and the outcome that satisfies the patient are two different things, and the regulatory system, by design, only knows how to see the first.

Why a "realistic" trial would fail

Follow this to its uncomfortable conclusion. Imagine a company that wanted to seek approval for how a product is actually used in the real world, with the real technique, the real dosing, the real full-face or combination or off-label application that defines competent modern practice. Imagine it designed a pivotal trial to reflect that reality honestly. It would almost certainly fail. The very things that make real-world aesthetic practice effective, the individualization, the technique dependence, the artful deviation from a rigid protocol, are the same things that introduce variability, and variability is the enemy of a clean statistical separation on a validated scale. A trial built to mirror reality would be too noisy, too dependent on the injector, too far from the sterile single-variable comparison the regulatory bar requires. It would not produce the tidy, powered, reproducible improvement an approval demands. So companies do the only thing they can. They design trials to win approvals rather than to describe practice, isolating a narrow indication and a standardized technique that will generate the required statistical signal. Then they release the product into a market that immediately uses it in ways the trial never studied. The label is not a description of the product. It is a description of the study, and the study was engineered to satisfy a bar borrowed from oncology rather than to capture what the product does on a Tuesday afternoon in an actual practice.

The non-responder fallacy

Nowhere does this disconnect produce more confusion than in the casual, constant misuse of a single clinical term, the "non-responder." It has quietly become the industry's favorite explanation for any disappointing toxin result, and used that way it is almost always wrong. A true non-responder is a specific and relatively rare phenomenon, a patient who has developed neutralizing antibodies against the toxin that inactivate it before it can work, an immunological resistance with a real mechanism and a real definition. That is what the term means. It is not what the term is used to describe. In practice, "non-responder" gets applied to any patient whose result underwhelmed. The actual cause is far more often something entirely correctable: a poor assessment of the patient's anatomy and muscle strength, an inadequate dose, an injection technique that missed its target, or the wrong product selected for the job. Labeling those patients non-responders is more than imprecise. It is a small act of intellectual laziness that lets everyone off the hook, converting a fixable failure of assessment or dosing or technique into an immutable property of the patient. It is a symptom of the larger problem. An industry so unaccustomed to discussing the real determinants of its outcomes reaches for a pseudo-scientific label rather than confront the technique-dependent, off-label, deeply human reality of how these products actually perform.

How we might actually solve this

The disconnect is structural, but it is not unfixable. The solutions begin with admitting that a regulatory framework borrowed from oncology is the wrong instrument for an elective, quality-of-life category, and that closing the gap will require building new instruments rather than complaining about the old one.

The first move is to take real-world evidence seriously as a formal input rather than an anecdotal footnote. That means building pragmatic registries that capture how products actually perform across real techniques and real practices. It also means creating regulatory pathways that let post-market evidence expand and refine labels toward the reality of use, rather than freezing them at the artificial moment of approval. The second is to develop and validate patient-reported outcome measures that can stand alongside investigator-assessed scales, so that satisfaction, natural movement, and the lived experience of a result become measurable endpoints rather than unmeasured externalities. The third is to decouple technique and training from the label, building rigorous, standardized certification for the real-world application of these products. The enormous variable of injector skill, which the regulatory process deliberately holds constant and the market cannot, would finally have a system of accountability attached to it. The fourth is to insist on precise nomenclature as a matter of professional discipline. Reserve "non-responder" for confirmed neutralizing antibodies, and force the industry to name the real causes of suboptimal results, because a field that cannot describe its own failures accurately cannot fix them. Underneath all of these sits the largest and most necessary shift, the development of a distinct standard of clinical meaningfulness for aesthetics, separate from the statistical-significance bar imported from therapeutic medicine. It would treat this as a category where the meaningful question is whether a patient is genuinely better off. It would build its evidence and its claims around that question instead.

Questions worth sitting with

Any leadership team operating in this category should be willing to ask a few questions the regulatory framework encourages them to avoid.

1. How much of your product's real-world use falls outside the indication you actually studied, and what is your honest plan for the truth living in that gap?
2. Does your label describe a result a patient will recognize, or a statistical endpoint engineered to clear a bar borrowed from oncology?
3. When your product underperforms in the field, do you know whether the cause is the patient, the dose, the technique, or the assessment, or do you reach for "non-responder" and stop asking?
4. And the question the whole industry has deferred for too long: what would it take to build a standard of clinical meaningfulness for aesthetics, and who benefits from the fact that no one has?